NotSoSillyCybn
Posted - 1 minute ago
$JAZZ went through the same thing GHB wasn’t legal. Look at her now. Don’t be dumb buy $CYBN
OpenOutcrier
Posted - 3 hours ago
$ZYME (+10.0% pre) $JAZZ Jazz stock Zymeworks stock gain on FDA nod - SA https://ooc.bz/l/48936
DonCorleone77
Posted - 5 hours ago
$JAZZ $ZYME Zymeworks, Jazz Pharmaceuticals announce FDA approval of Ziihera Zymeworks (ZYME) announced, with Jazz Pharmaceuticals (JAZZ), that the U.S. FDA has granted accelerated approval of Ziihera 50mg/mL for injection for intravenous use for the treatment of adults with previously-treated, unresectable or metastatic HER2-positive biliary tract cancer, as detected by an FDA-approved test. Ziihera was approved under accelerated approval based on a 52% objective response rate and a median duration of response of 14.9 months as determined by independent central review. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. The approval of Ziihera, which previously received Breakthrough Therapy Designation from the FDA for this indication, is an important advance and offers the first and only dual HER2-targeted bispecific antibody and chemotherapy-free treatment for patients living with BTC. In late 2022, Zymeworks entered into a license and collaboration agreement with Jazz Pharmaceuticals Ireland Limited, for the exclusive development and commercialization rights to zanidatamab across all indications in the United States, Europe, Japan and all other territories except for those Asia Pacific territories previously licensed by Zymeworks. This collaboration allowed the company to leverage Jazz's global commercial infrastructure, together with BeiGene's complementary strengths in certain Asia Pacific countries, to enable the global, rapid advancement of zanidatamab in multiple tumor types with the potential to provide a foundational HER2-targeted therapy for patients with difficult-to-treat cancers and limited treatment options. Under the terms of the Jazz license and collaboration agreement, Zymeworks has earned a milestone payment of $25M based on the FDA approval in BTC. Zymeworks is also eligible to receive up to a further $500M in regulatory milestone payments and $862.5M in commercial milestone payments, as well as tiered royalties of 10% to 20% of net sales by Jazz.
DonCorleone77
Posted - 16 hours ago
$JAZZ Jazz Pharmaceuticals announces FDA approval of Ziihera in BTC Jazz Pharmaceuticals "announced the U.S. Food and Drug Administration accelerated approval of Ziihera 50mg/mL for injection for intravenous use for the treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer, or BTC, as detected by an FDA-approved test.1 Ziihera was approved under accelerated approval based on a 52% objective response rate and a median duration of response of 14.9 months as determined by independent central review. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.1 The Phase 3 HERIZON-BTC-302 confirmatory trial is ongoing to evaluate zanidatamab in combination with standard-of-care therapy versus standard-of-care therapy alone in the first-line setting for patients with HER2-positive BTC. The FDA approval of Ziihera is based on compelling data from the HERIZON-BTC-01 trial, which included the evaluation of zanidatamab as a single agent in previously treated HER2-positive BTC and is the largest Phase 2b clinical trial to date specifically for this patient population. The trial achieved its primary endpoint of confirmed objective response rate by independent central review and results were presented at the American Society of Clinical Oncology Annual Meeting 2023, published in The Lancet Oncology, and included in the 2023 Best of ASCO(R) program. Longer follow-up data showing improvement upon previously reported DOR were reported at the ASCO Annual Meeting 2024."
Biotech2424
Posted - 17 hours ago
$CHRS This company has it all. Growth, pipeline, cash… this is the best risk adjusted biotech. Perfect for holders and acquirers.
Jazz should acquire them they bought Celator for billions. This is like plug and play instant scratch off for any buyer. $JAZZ
JaelynnBanks
Posted - 1 day ago
$JAZZ $IONS LFG, expected this to move higher. Also, your thoughts on MYNZ? Who's behind the 30M share offering deal? 👀 And how could the Thermo Fisher (TMO) partnership ($210B market cap) reflect this stock movement and PR buzz everywhere on socials?
PennySimka
Posted - 1 day ago
[ $JAZZ $IONS] LFG, expected this to move higher. Also, your thoughts on MYNZ? Who's behind the 30M share offering deal? 👀 And how could the Thermo Fisher (TMO) partnership ($210B market cap) reflect this stock movement and PR buzz everywhere on socials?
erevnon
Posted - 3 days ago
Baird maintains Jazz Pharmaceuticals $JAZZ at Outperform and raises the price target from $154 to https://marketsblock.com/stock-upgrades-and-downgrades/
Biotech2424
Posted - 4 days ago
No vascular toxicity like Keytruda. Great aspect for Loqtorzi should make this into mini-blockbuster with other indications approved. NPC alone $150-200 million revenues layer in a few more keep doubling and tripling revenues at Coherus - potential $350 million 2025 revs trading at .35 forward sales while industry avg multiple is 3.5 sales. 10x upside… $CHRS $JAZZ $KPTI
MayLucas
Posted - 5 days ago
😏🚀 MYNZ We know the date of the reverse split (RS) if there will be one, but possibly a Nasdaq extension will be granted. Last time it traded, 50 million and 19 million heavy shorts attacked. Now, it has huge credibility after the TMO partnership and the meeting. The company will decide by November 25th whether or not to do an RS based on Nasdaq's response. Anyway, after the RS, I'm not worried about what happens next. A $210 billion partner TMO signing a deal with a penny stock has never happened before. I will be loading heavy on Monday. This will go to the moon like the DRUG stock recently did. The price target (PT) is $50. The squeeze will be parabolic. $GRFS $JAZZ
GPS_OS_21_vs_SOC_5
Posted - 6 days ago
$SLS Don't Get Short Conned, Institutional Funds are accumulating .... SLS will instantly be worth Multiple Billions when Gps P3 Results Come in - This Quarter. $cpxx was a $50M Mcap when it released its P3 AML data showing a 4 month OS benefit. It was a $750M Mcap 3 weeks later and then got bought by $jazz for $1.5B 2 months after that. Something Similar is about to happen Here. ps GPs Treats 5x the number of AML Patients as Vyxeos, plus PR/R Ovarian Cancer and Mesothelioma.
DragonTiger
Posted - 1 week ago
$JAZZ Goldman used to have $190 PT. Is it still valid? Just asking
Ladd220
Posted - 1 week ago
$JAZZ Fair market value is still $200 a share plenty of upside from here. Will continue to add.
Fab23IT
Posted - 1 week ago
$JAZZ i missed to buy this stock few days ago at $ 110, is it still a good time to jump in or better to wait for a poolback? Thank you all..
esque1954
Posted - 1 week ago
$JAZZ This company will be bought out with a 7.5 billion market cap.
d_risk
Posted - 1 week ago
$JAZZ - 10Q - Updated Risk Factors New risk factors for JAZZ in 2024 include supply chain vulnerabilities, reliance on single-source suppliers, and regulatory compliance challenges amid geopolitical tensions. https://d-risk.ai/JAZZ/10-Q/2024-11-07
erevnon
Posted - 2 weeks ago
Needham reiterates Jazz Pharmaceuticals $JAZZ at Buy and maintains a price target of https://marketsblock.com/stock-upgrades-and-downgrades/
silentfury
Posted - 2 weeks ago
$JAZZ $120 soon
ringo2112
Posted - 2 weeks ago
$JAZZ they crushed earnings like Trump CRUSHED harris
Vacationforever25
Posted - 2 weeks ago
$JAZZ
DonCorleone77
Posted - 2 weeks ago
$JAZZ Jazz Pharmaceuticals raises FY24 adjusted EPS view to $19.50-$20.60 Prior view $19.20-$20.30, consensus $19.59. Backs FY24 revenue view $4B-$4.1B, consensus $4.04B.
DonCorleone77
Posted - 2 weeks ago
$JAZZ Jazz Pharmaceuticals reports Q3 adjusted EPS $6.61, consensus $5.50 Reports Q3 revenue $1.054B, consensus $1.04B. "Jazz once again delivered record revenues of more than $1.05 billion and a 14% year-over-year increase in revenue from our key growth drivers combined. We continue to see robust patient demand for Xywav with approximately 400 net patient additions in the third quarter, supported by physician and patient appreciation of a low-sodium treatment option. Strong sleep1 performance coupled with continued Epidiolex performance gives us confidence in maintaining our total revenue guidance of $4.0 to $4.1 billion for 2024," said Bruce Cozadd, chairman and chief executive officer, Jazz Pharmaceuticals. "We're preparing for the anticipated launch of zanidatamab in the fourth quarter in 2L BTC, where there remains a high unmet medical need. We expect to provide the first chemotherapy-free dual HER2-targeted bispecific antibody indicated for BTC as well as an opportunity for HCPs to gain important experience ahead of future indications. In addition, results from the Phase 3 IMforte trial were highly encouraging, and we plan to submit an sNDA for Zepzelca in the first half of 2025 to support expansion into the 1L maintenance setting in ES-SCLC."
Iwillplay
Posted - 2 weeks ago
$JAZZ Throw me a bone so I can leave?
Estimize
Posted - 2 weeks ago
$JAZZ reports after the close, Estimize Consensus -0.06 EPS and +1.81M Revs compared to WS
http://www.estimize.com/jazz/fq3-2024?utm_conten
insiderbuyingselling
Posted - 2 weeks ago
$JAZZ new insider selling: 1000 shares. http://insiderbuyingselling.com/?t=JAZZ
LarryYMB
Posted - 10/31/24
$JAZZ game over mofos, even millions thrown at attorneys can't save your sorry ass.
Estimize
Posted - 10/28/24
$JAZZ analysts on Estimize are expecting 6.16% YoY revenue growth for Q3, down from 6.95% in Q2 [Reporting 11/06 AMC]
http://www.estimize.c
Jeffmids
Posted - 10/24/24
$JAZZ Dumped on myself from GWP takeover -junk status .
Bong_PreahChan
Posted - 10/24/24
$IXHL Dr. Barbato (CMO) moves over from $JAZZ
